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Abstract
Background: The aberrant activation of Ras signaling is associated with human diseases including hematological
malignancies and vascular disorders. So far the pathological roles of activated Ras signaling in hematopoiesis and
vasculogenesis are largely unknown.
Methods: A conditional Cre/loxP transgenic strategy was used to mediate the specific expression of a constitutively
active form of human N-Ras in zebrafish endothelial and hematopoietic cells driven by the zebrafish lmo2
promoter. The expression of hematopoietic and endothelial marker genes was analyzed both via whole mount in
situ hybridization (WISH) assay and real-time quantitative PCR (qPCR). The embryonic vascular morphogenesis was
characterized both by living imaging and immunofluorescence on the sections with a confocal microscopy, and
the number of endothelial cells in the embryos was quantified by flow cytometry. The functional analyses of the
blood circulation were carried out by fluorescence microangiography assay and morpholino injection.
Results: In the activated N-Ras transgenic embryos, the primitive hematopoiesis appeared normal, however, the
definitive hematopoiesis of these embryos was completely absent. Further analysis of endothelial cell markers
confirmed that transcription of arterial marker ephrinB2 was significantly decreased and expression of venous
marker flt4 excessively increased, indicating the activated N-Ras signaling promotes the venous development at the
expense of arteriogenesis during zebrafish embryogenesis. The activated N-Ras-expressing embryos showed
atrophic axial arteries and expansive axial veins, leading to no definitive hematopoietic stem cell formation, the
blood circulation failure and subsequently embryonic lethality.
Conclusions: Our studies revealed for the first time that activated N-Ras signaling during the endothelial
differentiation in vertebrates can disrupt the balance of arterial-venous specification, thus providing new insights
into the pathogenesis of the congenital human vascular disease and tumorigenic angiogenesis.
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Background
RAS proteins are small GTPases that have been proved
to be essential for the control of cell proliferation,
survival, and differentiation [1,2]. Ras genes are evolu-
tionally and functionally conserved in all eukaryotic or-
ganisms. In mammals, the 3 Ras genes encode 4 highly
homologous proteins: H-, N-, and K-RAS 4A and 4B.
The four RAS proteins interact with a common set of
activators and effectors, and thus share many bio-
chemical and biological functions [1]. Both Ras genes
and components of Ras signaling pathways, including
membrane receptor tyrosine kinases (RTKs), Ras-GEFs,
Ras-GAPs, and downstream cytoplasmic kinases (RAFs),
are reported to be frequently mutated in diverse human
cancers and congenital developmental diseases [3]. In
particular, activated mutations of N-Ras gene have been
detected in human myeloid leukemias with high fre-
quency [3], ranging from 15% to 60%, and several
myeloid leukemia-like mice models were established by
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bone marrow transduction/transplantation [4], trans-
genic [5] and knock-in [6,7] model systems, suggesting
that the oncogenic N-Ras can initiate myeloid leukemias,
nevertheless, the long latency and the requirement of co-
operative genetic lesions in those models imply that the
activated N-Ras signaling alone is insufficient to trans-
form the normal hematopoietic cells into leukemic cells.
So far the direct effect of oncogenic N-Ras signaling in
hematopoietic cells remains mostly unknown.
Abnormal activation of Ras signaling has been repor-
ted to be involved in tumorigenic angiogenesis [8] and
congenital vascular developmental diseases [3]. Capillary
Malformation-Arteriovenous Malformation (CM-AVM)
is a cutaneous congenital vascular disease that is com-
pound of Capillary Malformation (CM) and Arterio-
venous Malformation (AVM), and in which the arterial
and venous vessels in the skin are connected directly to
one another without an intervening capillary bed [9].
Rasa1 gene encodes p120ras-GAP which functions by
inhibiting the activity of RAS proteins, and heterozygous
inactivating rasa1 mutations were detected and proved
to be the causal genetic lesion for CM-AVM [9], sug-
gesting an important role of hyperactive Ras signaling in
this disease. So far whether the rasa1 mutations function
through an endothelial cell-autonomous manner is still
unknown. In addition, the reciprocal signaling between
EphrinB2 (artery specific gene) and its receptor EphB4
(vein specific gene) is critical for the formation of capil-
lary beds [10], and it is proposed that a defect in ephrins
or their receptors may be a causative factor in the for-
mation of Arteriovenous Malformation (AVM) [11]. And
notch pathway mutant (dll4 and Rbpsuh genes) mice
embryos exhibit defects in arterial specification of nas-
cent blood vessels and develop Arteriovenous Malforma-
tions [12]. However, the pathogenesis of CM-AVM or
AVM is largely unknown.
In human N-RAS protein, a point mutation resulting
in the substitution of glycine to aspartic acid at codon
12 (G12D) has been proved to impair GAP-stimulated
GTP hydrolysis, making the N-Ras signaling constitu-
tively activated [13], hereafter referred as hNRASD12.
Lmo2 is a transcriptional factor specifically expressed in
the hemangioblasts (the bipotential hemato-endothelial
progenitor cells) and hemangioblasts-derived primitive
hematopoietic and endothelial cells [14,15]. we recently
established and functionally characterized the transgenic
Tg(lmo2:Cre) fish expressing the Cre recombinase under
the control of zebrafish lmo2 promoter [16], and further
showed that Tg(lmo2:Cre) mediated expression of dom-
inant negative C/ebpα and Bmi1 in zebrafish lmo2
+ cells
each extended short-lived hematopoietic stem/progeni-
tor cell life span and induced lethal dyserythropoiesis
[17]. To explore the roles of aberrant activation of
N-Ras signaling in hematopoiesis and vasculogenesis,
we used the Tg(lmo2:Cre) to mediate the expression
of hNRASD12i nlmo2
+ cells of zebrafish embryos,
and showed that the activated N-Ras signaling in the
hNRASD12 transgenic embryos didn’t induce overt hema-
topoietic or leukemic phenotypes, while caused severe
defective vasculogenesis and subsequently embryonic le-
thality. The venous cell fate determination was abnormally
enhanced at the expense of the arteriogenesis, indicating
an endothelial cell-autonomous role of Ras signaling in
the arterial-venous specification.
Results
Establishment of transgenic zebrafish lines with
hemogenic and endothelial cell-specific expression of
human oncogenic N-Ras
To address the roles of disease-associated activation of
N-Ras signaling in hematopoietic and endothelial sys-
tems in vivo, we induced specific expression of human
NRASD12 (hNRASD12) in these tissues using the Cre-
loxP system under the control of lmo2 promoter in the
zebrafish.
We first established the Tg(β-actin:LDL-hNRASD12)
lines (Figure 1A) and obtained 7 heterozygous stable
lines that ubiquitously expressed the fluorescent DsRed
protein during embryonic development (data not shown).
All 7 lines were crossed to the heterozygous Tg(lmo2:Cre)
fish individually to generate four different genotypes in the
progeny: hNRASD12
-Cre
- (wild-type), hNRASD12
-Cre
+,
hNRASD12
+Cre
- (β-actin:LDL-hNRASD12;wild-type)a n d
hNRASD12
+Cre
+ (β-actin:LDL-hNRASD12; lmo2:Cre). In
particular, the β-actin:LDL-hNRASD12;lmo2:Cre double
transgenic embryos derived from line 4 showed robust ex-
pression of hNRASD12 transcripts in the intermediate cell
mass (ICM) region at 22 hours post fertilization (hpf)
(Figure 1B), which mostly resembled the expression pat-
tern of endogenous lmo2 transcripts in wild-type embryos
at the same stage (Figure 1D). And all the β-actin:LDL-
hNRASD12;wild-type embryos, hereafter referred as con-
trol embryos, showed no detectable expression of
hNRASD12 transcripts in the ICM region (Figure 1C).
Consistently, the expression of hNRAS protein was only
detected in the β-actin:LDL-hNRASD12;lmo2:Cre embryos
at 28 hpf (Figure 1E), hereafter referred as hNRASD12
embryos.
Elevated Ras signaling by overexpression of hRASD12 has
no impact on primitive hematopoiesis
After confirmation of the hNRASD12 expression in the
transgenic embryos, we examined the effect of activated
N-Ras signaling on the specification and differentiation
of blood cells in the hNRASD12 embryos. Like mam-
malian, zebrafish hematopoiesis includes two consecu-
tive waves of hematopoiesis: primitive and definitive
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from the anterior and posterior lateral plate mesoderm
and produces erythrocytes, macrophages, and granulocy-
tes, providing blood cells for early embryogenesis [18].
The definitive hematopoietic stem cells (HSCs) emerge
from the hemogenic endothelium at the ventral wall of
the dorsal aorta from 30 hpf onward, called endothelial
hematopoietic transition (EHT) [19,20], and generate all
types of blood cells in adulthood [18]. To characterize
the hematopoietic phenotypes in the hNRASD12 em-
bryos, we performed whole mount in situ hybridization
(WISH) analysis to examine the hematopoietic markers
expression [21,22] in the control and hNRASD12 em-
bryos at 18 and 22 hpf, including lmo2 (hemangioblasts),
gata1 (primitive erythroid progenitors), αe1 globin (ma-
ture erythrocytes), pu.1 (primitive myeloid progenitors),
l-plastin (primitive macrophages), mpo (neutrophils),
cmyb and runx1 (HSCs). The results showed that ex-
pression of those primitive hematopoietic markers is
not affected in the hNRASD12-expressing embryos
(Figure 2A & B). Consistent with the WISH results, the
real-time quantitative PCR (qPCR) analysis showed no
significant difference at the expression level of these
markers between the hNRASD12 and control embryos,
Figure 1 Validation of hNRASD12 expression in the β-actin:LDL-hNRASD12;lmo2:Cre transgenic embryos. (A) Diagrammatic scheme of the
β-actin-LDL-hNRASD12 transgenic construct. (B-D) The expression analyses of the hNRASD12 transcripts via whole mount in situ hybridization
(WISH) in the β-actin:LDL-hNRASD12;lmo2:Cre embryo (hereafter referred as hNRASD12 embryo) (B) and β-actin:LDL-hNRASD12;wild-type embryo
(hereafter referred as control embryo) (C) respectively at 22 hours post fertilization (hpf), and lom2 transcripts in the wild-type embryo at 22 hpf
(D). Black arrows denote the location of the intermediate cell mass (ICM) region. (E) Confirmation of the expression of hNRAS protein in the
hNRASD12-embryos at 28 hpf via western blotting analysis.
Figure 2 The primitive erythropoiesis and myelopoiesis are not affected by the expression of hNRASD12. (A-B) WISH analysis of primitive
hematopoietic markers expression in the control embryos and hNRASD12expressing embryos respectively at 18 (A) and 22 hpf (B). (C-D)
Verification of the expression level of the hematopoietic markers in the control or hNRASD12 embryos at 18 (C) and 22 hpf (D) via real-time
quantitative PCR. Data shown are means ± SEM of at least three independent experiments.
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ment of primitive blood cells (Figure 2C & D). However,
the definitive HSCs marked by runx1 and cmyb couldn’t
be detected in the aorta-gonad-mesonephros (AGM) re-
gion of the hNRASD12 embryos (Figure 3A-D). Accor-
ding to the defective blood circulation and dorsal aorta
formation in the hNRASD12 embryos described below,
the lack of definitive hematopoiesis is likely the second-
ary effect of the vascular defects, as both the normal
blood circulation and dorsal aorta formation have been
proven to be indispensable for the emergency of defini-
tive HSCs in the AGM region [23,24], thus preventing
from directly dissecting the role of activated N-Ras
signaling in definitive hematopoiesis. Taken together,
these data show that the oncogenic N-Ras signaling
in the zebrafish lmo2
+ cells doesn’t induce directly
hematopoietic or leukemic phenotypes in the trans-
genic embryos.
Vascular morphogenesis defects in hNRASD12-expressing
transgenic embryos
Expression of hNRASD12 under the lmo2 promoter will
lead to expression both in the hematopoietic and endo-
thelial lineages, so we then examined the circulatory sys-
tem and found the hNRASD12 embryos at 28 hpf lacked
blood circulation both in head and trunk vessels, and
the blood cells were accumulated in the trunk axial ves-
sels and heart chambers (Figure 4B & D, and Additional
files 1 and 2: movie S3 and S4) in comparison of normal
circulation in the control embryos (Figure 4A & C,
and Additional files 3 and 4: movie S1 and S2). The
hNRASD12 embryos died between 5 and 8 days post
fertilization (dpf) with the persistent lack of blood circu-
lation. To validate the blockage of circulation was specif-
ically induced by the expression of human NRASD12,
we designed a rescue experiment by using an antisense
ATG morpholino (MO) targeting the translational initi-
ation site of this transgenic hNRASD12. Firstly, the ef-
ficiency of the hNRAS MO was confirmed by efficiently
blocking both the translation of the GFP mRNA re-
porter (Additional file 5: Figure S1A-D) in wild-type em-
bryos and the expression of hNRASD12 protein in the
hNRASD12 embryos (Additional file 5: Figure S1E).
Compared with the control MO, the hNRAS MO that
was injected into one-cell stage embryos derived from
the crossing between the heterozygous Tg(lmo2:Cre) and
Tg(β-actin:LDL-hNRASD12) fish restored the blood cir-
culation of hNRASD12 embryos to a comparable level as
that of control embryos (Figure 4E), indicating the bloc-
ked blood circulation is specifically induced by hNRASD12
ectopic expression. Considering the primitive hemato-
poiesis of hNRASD12 embryos is normal, we hypothesized
that the congestion of circulation resulted from the de-
fective cardiovascular development. We then checked the
cardiovascular structure and function by using the fluo-
rescent microangiography assay. The fluorescein-coupled
latex beads were injected into the inflow tract of the
atrium of the control and hNRASD12 embryos respect-
ively, and were observed to perfuse the whole vascular sys-
tem of the control embryos in five minutes (Additional
file 5: Figure S2A, upper panel). However, it took over 30
minutes for injected beads to passively diffuse into the an-
terior trunk of the hNRASD12 embryos (Additional file 5:
Figure S2A, lower panel), indicating the activated Ras sig-
naling disrupts the circulation. In particular, the consecu-
tive accumulation of fluorescent beads in the trunk of
hNRASD12 embryos (Additional file 5: Figure S2A, lower
panel) suggested the existence of only one axial vascular
tube. We further examined the function of the heart of
hNRASD12 embryo by counting the rate of heartbeats,
and the result showed that the average rate of heartbeats
in the hNRASD12 embryos at 30 hpf was only slightly
slower than that of control embryos (Additional file 5:
Figure S2B), suggesting the phenotype of heartbeat con-
tributes little to the circulation blockage.
To further analyze the vascular defect in the hNRASD12
embryos, we crossed the Tg(flk1:GFP) fish [25], an endo-
thelial reporter transgenic line, with Tg(β-actin:LDL-
hNRASD12) fish to obtain the double transgenic progeny,
which were raised to adulthood and subsequently cros-
sed to Tg(lmo2:Cre) fish to generate the β-actin:LDL-
hNRASD12;flk1:GFP;lmo2:Cre (referred as hNRASD12;
flk1:GFP) embryos. In the trunk of β-actin:LDL-
Figure 3 The definitive hematopoiesis is disrupted in the
hNRASD12-expressing embryos. (A-D) WISH analysis of runx1
+ and
cmyb
+ definitive hematopoietic stem cells (HSCs) in the aorta-gonad
-mesonephros (AGM) region of the trunk in the control (A, C) and
hNRASD12 embryos (B, D) at 30 hpf (arrows).
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GFP) embryos at 28 hpf, the primary blood vessels
consisted of the dorsal aorta (DA) and posterior cardinal
vein (PCV), and the intersegmental vessels (ISVs) formed
by sprouting from the dorsal aorta (Figure 5A) [26]. How-
ever, hNRASD12;flk1:GFP embryos failed to form mor-
phologically distinct DA or PCV, and the ISVs were also
defective (Figure 5B). The results of immunofluorescence
analysis on transverse sections showed the presence of
only one vascular tube in the trunk of hNRASD12-
expressing embryo (Figure 5C & D). Furthermore, the
morphology of head vasculature was also examined, in the
control;flk1:GFP embryos at 28 hpf, the paired bilateral lat-
eral dorsal aortas (LDAs) merged backward into single
dorsal aorta at the boundary between head and trunk, and
the posterior cardinal vein (PCV) split forward into a pair
of vessels in the cranial trunk, then the branches of PCV
emptied into the common cardinal veins (CCVs) on the
either side of yolk, which came into the sinus venous of
the heart (Figure 5E & G) [26]. Unlike that of control;flk1:
GFP embryos, the LDAs of hNRASD12;flk1:GFP embryos
were evidently atrophic while CCVs and the bifurcation of
PCV were greatly expanded, however, the primordial
hindbrain channels (PHBCs), the primary veins in the
head at this stage, seemed normal (Figure 5F & H). In
addition, basilar artery (BA), the main artery in the hind-
brain of the zebrafish embryo formed by endothelial
sprouting of PHBCs [27], was lost in the hNRASD12-ex-
pressing embryo (Figure 5I & J). Taken together, our ob-
servations suggested that the activated N-Ras signaling in
the zebrafish lmo2
+ cells caused the abnormal assembly of
the axial blood vessels and the defective arteries formation
and expansion of veins in the head vasculature system of
the hNRASD12 embryos.
hNRASD12 promotes venous fate specification at the
expense of arterial fate in zebrafish
As Ras signaling has been proved to be important for
cell proliferation [1,2], the frequencies of endothelial
cells in the hNRASD12;flk1:GFP and control;flk1:GFP
embryos at 28 hpf were respectively quantified by flow
cytometry analysis, and the result showed no significant
difference in the frequencies of GFP
+ endothelial cells
between hNRASD12-expressing and control embryos
(Figure 6A). We further characterized the arterial and
venous cells lineages respectively in the hNRASD12 em-
bryos by performing WISH analysis. EphrinB2, hRT, dll4
and grl genes are specifically expressed in the arterial
cells of wild-type embryo’s trunk region [23,27], while
ephB4, flt4 and dab2 mark the venous cells [28]. The
result of WISH showed that the arterial cells were evi-
dently reduced in hNRASD12-expressing embryos com-
pared with control embryos (Figure 6B, B’, D, and D’),
and failed to form an intact dorsal aorta (Figure 6C, C’,
E, and E’); On the contrary, the venous cells in the
hNRASD12 embryos were greatly expanded and organi-
zed to be an enlarged vein-like vascular tube (Figure 6F-I
and F’-I’). To confirm that expression of hNRASD12 in-
duced an unbalanced arterial-venous specification in the
same embryo, we performed 2-color WISH analysis with
digoxigenin-labeled ephrinB2 and fluorescein-labeled flt4
antisense probes, and observed the expansion of venous
cells and reduction of arterial cells occurring in a single
hNRASD12-expressing embryo (Figure 6J’ &K ’) compared
Figure 4 The expression of hNRASD12 blocks the blood circulation. (A-D) Morphology of the control (A & C) and hNRASD12 embryos
(B & D) at 28 hpf. The arrows mark the blood flow in the trunk and heart of control embryo, and the triangles denote the accumulated blood
cells in the trunk and heart of hNRASD12 embryo. (E) The assessment of blood circulation in wild-type, control and hNRASD12 embryos after
injection of control and hNRAS morpholino (MO) respectively; the numbers on the right of the bars indicate the amount of the embryos being
counted, and representative results obtained from three independent experiments.
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from WISH with dll4, grl,a n ddab2 probes also supported
the above observations (Additional file 5: Figure S3 A-F)
that almost the entire vascular tube in the trunk of
hNRASD12 embryo consists of venous endothelial cells.
Vasculogenesis is referred to as the de novo formation
of the blood vessels, involving the differentiation, pro-
liferation and migration of endothelial cells [29]. In
zebrafish, the angioblasts at the bilateral posterior lateral
plate mesoderm migrate medially to form the vascular
cord between 14 and 18 hpf, meanwhile the arterial-
venous specification is established [23,25]. Then the ven-
ous cells sprout ventrally to separate from the arterial
cells between 21 and 24 hpf, called arterial-venous se-
gregation [30]. Subsequently, the dorsal arterial cells
organize to be dorsal aorta by cord hollowing [31], while
the posterior cardinal vein forms by embrace of the
hematopoietic cells [30]. To figure out which of the
above developmental processes is affected firstly by the
expression of hNRASD12, we used WISH analysis to de-
tect the arterial-venous specification at earlier stages be-
fore 28 hpf, and found that arterial-venous defects in the
hNRASD12-expressing embryos appeared as early as 20
hpf (Figure 7A-L), when the identity of arterial-venous
cell fate is just established [25], indicating N-Ras signal-
ing regulates the specification of arterial and venous cells
before the arterial-venous segregation and onset of cir-
culation. In addition, previous studies have revealed an
important role of the angioblasts migration between 14
and 18 hpf in the arterial-venous specification [23,32].
To examine whether the constitutively activated N-Ras
signaling affects the medial migration of angioblasts, we
used flk1 as a probe to trace this process. The result
showed the medial migration began at 14–15 hpf, and
nearly all angioblasts arrived at the midline at 17–18 hpf
in the control embryo (Figure 8A-E), and hNRASD12-ex-
pressing embryo showed a similar pattern (Figure 8F-J),
indicating the activated N-Ras signaling specifically affects
the arterial-venous specification in an angioblasts-medial-
migration-independent manner.
To further confirm that the defects in the assembly of
the blood vessels and the arterial and venous fate deci-
sions are specifically induced by the transgenic expres-
sion of hNRASD12, we knocked down the hNRASD12
expression using hNRAS MO in the hNRASD12 em-
bryos. The trunk vasculature was imaged under a con-
focal microscopy and arterial and venous cells in the
region were evaluated by WISH analysis of arterial-
Figure 5 Vasculogenesis is disrupted in hNRASD12-expressing transgenic embryos. (A-B) Confocal images of trunk vasculature of living
control; flk1:GFP (A) and hNRASD12;flk1:GFP embryos (B) at 28 hpf. DA, dorsal aorta; PCV, posterior cardinal vein; ISV, intersegmental vessel. (C-D)
Mid-trunk transverse sections of control;flk1:GFP (C) and hNRASD12;flk1:GFP embryos (D) at 28 hpf stained by GFP antibody (green) and Phalloidin-
TRITC (red). NT, neural tube; NC, notochord. (E-J) Confocal images of head vasculature of living control;flk1:GFP (E, G, I) and hNRASD12;flk1:GFP
embryos at 28 hpf (F, H, J). LDA, lateral dorsal aorta; PHBC, primordial hindbrain channel; CCV, common cardinal vein; BA, basilar artery. The red
dotted lines denote the boundaries of the CCVs and PCVs respectively.
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trol MO, the hNRAS MO efficiently rescued both the
defective assembly of blood vessels (Additional file 5:
Figure S4A) and the unbalanced arterial-venous fates of
the endothelial cells (Additional file 5: Figure S4B) in the
trunk region of hNRASD12 embryo, indicating the de-
fective vasculogenesis in the transgenic embryos is spe-
cifically caused by hNRASD12 expression.
Thus we conclude that the activated N-Ras signaling
by expressing hNRASD12 in lmo2
+ cells disrupts the
balance of the arterial-venous specification, where the
venous fate decision is enhanced while the arterial speci-
fication is repressed, which in turn causes abnormal
assembly of main blood vessels and the defect in the de-
velopment of intersegmental vessels, leading to blockage
of blood circulation and embryonic lethality. Neverthe-
less, expression of hNRASD12 affects neither the endo-
thelial specification from mesoderm cells, the medial
migration of angioblasts, nor the proliferation of endo-
thelial cells.
The hierarchical signaling molecules, including sonic
hedgehog (Shh), vascular endothelial growth factor A
(VEGFA), phospholipase C gamma-1 (Plcg1), and notch
have been shown to be essential for the arterial cell
fate decision [33]; while chicken ovalbumin upstream
promoter-transcription factor II (COUP-TFII), also known
as Nuclear Receptor 2F2 or NR2F2, is indispensable for
the venous specification [33]. To figure out whether
hNRASD12 regulates the transcriptional expression of
those genes, we performed WISH analysis with ribo-
probes of these arterial-venous regulatory genes, and
found no significant difference between the control and
hNRASD12 embryos (Additional file 5: Figure S5A-F and
S5A’-F’).
Previous studies have shown that forced expression
of vegfaa121 in wild-type embryo could transform all
the endothelial cells into ephrinB2
+ arterial cells [34],
however, we observed the failure of hNRASD12 em-
bryos to respond to exogenous expression of vegfaa121
(Additional file 5: Figure S6A-E), indicating that N-Ras
signaling functions downstream of vegfa to negatively
regulate the vegfa induced arterial development.
Considering notch signaling has been proved to act
downstream of shh-vegfa signaling axis to regulate the
arterial endothelial differentiation in zebrafish [35], we
tried to rescue the hNRASD12-induced defective arterio-
genesis by injecting a transient transgenic construct into
the hNRASD12 embryos, in which a constitutively acti-
vated form of notch1 containing only the intracellular
domain (referred as NICD1) was driven by the zebrafish
flk1 promoter, however, no recovery of arteriogenesis
was observed in those injected embryos (data not shown),
implying defects caused by activated Ras is not through
disrupting the notch signaling.
Figure 6 Expression of hNRASD12 promotes venous specification at the expense of arterial fate during embryonic endothelial
differentiation. (A) Quantitation of total endothelial cells by flow cytometry analysis on the control;flk1:GFP and hNRASD12;flk1:GFP embryos at 28
hpf. Representative results obtained from three independent experiments. 2 tailed t-test of frequency of endothelial cells in hNRASD12;flk1:GFP
embryos vs control;flk1:GFP embryos shows no significant difference. (B-E’) WISH analysis of ephrinB2
+ and hRT
+ arterial cells in the trunk of control
(B-E, blue triangles) and hNRASD12 embryos (B’-E’, red triangles) at 28 hpf. (F-I’) WISH analysis of flt4
+ and ephB4
+ venous cells in the trunk of
control (F-I) and hNRASD12 embryos (F’-I’) at 28 hpf. The yellow square brackets mark the width of the venous strip in the trunk. (J-K’) 2-color
WISH analysis with digoxigenin-labeled ephrinB2 (white arrows) and fluorescein-labeled flt4 (white triangles) in control (J, K) and hNRASD12
embryos (J’, K’) respectively at 28 hpf.
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signaling in vasculogenesis
To assess the conservation between the human and
zebrafish N-Ras signaling, we compared the protein se-
quences of the human, mouse and zebrafish N-RAS, and
found that there is a high degree of sequence similarity
between the zebrafish and mammalian N-RAS with a
high identity of 95% in the critical H_N_K_Ras_like do-
main (G domain) (Additional file 5: Figure S7). To fur-
ther determine whether the activated zebrafish N-Ras
signaling has a conserved function in the vasculogenesis
as human N-Ras, we generated both lmo2:EGFP-2A-
hNRASD12 and lmo2:EGFP-2A-zNRASD12 transgenic
constructs, in which the zebrafish lmo2 promoter was
used to transiently direct the specific expression of
activating mutant of human and zebrafish N-Ras in
blood and vasculature respectively. The WISH analysis
showed that both the hNRASD12 and zNRASD12 tran-
scripts were appropriately expressed in the ICM region
(Additional file 5: Figure S8A), similar to the expression
pattern of endogenous lmo2 gene (Figure 1D), and the
expression of the human and zebrafish NRASD12 pro-
teins was also confirmed via western blotting assay
(Additional file 5: Figure S8B). The trunk vasculature
of embryos expressing the hNRASD12 or zNRASD12
was characterized under a confocal microscopy. And
compared to the embryos injected with lmo2:EGFP-
2A,b o t ht h ehNRASD12 and zNRASD12-expressing
embryos had only one vascular tube in the trunk
(Additional file 5: Figure S8C). Additional WISH ana-
lysis of the arterial marker ephrinB2 and venous mar-
ker flt4 genes showed large expansion of venous cells
population and nearly lack of the arterial cells in the
trunk region (Additional file 5: Figure S8C). These re-
sults strongly suggest a conserved function between
activated human and zebrafish N-RAS and that the
N-Ras signaling participate in regulating the zebrafish
vascular development.
Figure 7 Loss of arterial specification by hNRASD12 expression before arterial-venous segregation and onset of circulation. (A-H) WISH
analysis of arterial (ephrinB2
+, hRT
+) and venous (flt4
+, dab2
+) cells in the trunk of control (A, C, E, G) and hNRASD12 embryos (B, D, F, H) at 20 hpf
respectively. (I-L) 2-color WISH analysis with digoxigenin-labeled ephrinB2 (white arrows) and fluorescein-labeled flt4 (white triangles) in control
(I, J) and hNRASD12 embryos (K, L).
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In this study, we showed that transgenic overexpression
of activated human NRAS (hNRASD12) in zebrafish
lmo2
+ cells caused un-circulated vasculature, but had no
impact on the primitive hematopoiesis during embryo-
genesis. In particular, the expression of hNRASD12 pro-
moted the venous fate at the expense of arterial fate
during arterial-venous specification, indicating an im-
portant novel role of activated Ras signaling in vascular
morphogenesis.
Our whole mount in situ hybridization (WISH) and
quantitative RT-PCR analysis of the expression of
the hematopoietic markers showed the expression of
hNRASD12 in the lmo2
+ hemangioblasts neither af-
fected the specification or differentiation of the primitive
hematopoietic cells, nor induced any leukemic pheno-
types. However, the mice models expressing hNRASD12
exhibited leukocytosis and progressed to myeloid leuke-
mias [4-7]. The discrepancy between our zebrafish model
and those mice models is likely due to the difference in
the targeting cell type and the developmental window of
the NRASD12 expression. In the mice models, the expres-
sion of the NRASD12 was induced in the adult bone
marrow cells, the adult hematopoietic organs, and caused
dysplastic myelopoiesis/leukemias with long latencies (> 4
weeks), which highlight the possible requirement of a de-
finitive hematopoietic environment and the length of time
to accumulate cooperative genetic mutations for the de-
velopment of NRASD12-associated leukemia [36]. In our
study, the expression of hNRASD12 was activated during
the transient primitive hematopoietic stage and embryos
failed to develop through the definitive hematopoietic
stages due to lack of definitive hematopoiesis as a result of
the defective vasculogenesis, and early embryonic lethality
(5–8 days post fertilization), preventing the occur-
rence of the myeloid disorders and leukemias. Our re-
sults supported the concept that leukemogenesis is a
multistep process involvingc o o p e r a t i n gg e n e t i cm u t a -
tions [37], the elevation of RAS signaling by the expres-
sion of hNRASD12 alone in the short-lived primitive
hematopoietic cells was insufficient for leukemogenesis.
Whether the hyperactive Ras signaling caused by in-
activating RASA1 mutations in Capillary Malforma-
tion-Arteriovenous Malformation (CM-AVM) functions
through an endothelial cell-autonomous manner is still
unknown [9]. Here we showed that the expression of
oncogenic human N-Ras in the lmo2
+ cells disrupted
arterial-venous specification and angiogenesis in zebrafish
embryos, indicating an endothelial cell-autonomous role
of oncogenic ras signaling in vasculogenesis. Consistently,
the rasa1-deficient mice embryos are embryonic lethal
and exhibit atrophic dorsal aorta and disorganized pat-
terns of the intersegmental arteries [38]. The EphrinB2/
EphB4 signaling [10,11] and notch pathway [12] are in-
volved in the pathogenesis of Arteriovenous Malformation
(AVM), suggesting the direct genetic connection between
the arterial-venous specification and CM-AVM/AVM. In
our study, the transgenic expression of hNRASD12 in-
duces defective arterial-venous specification in zebrafish,
and this vertebrate genetic model may help us to further
dissect the pathogenesis of CM-AVM or AVM.
In mice, it has been demonstrated that the germ line
oncogenic Ras expression leads to embryonic lethality
[6,39], where the Protamine-Cre (PrmCre) mice medi-
ates constitutive and ubiquitous expression of oncogenic
KRASD12 (floxed knock-in) [39], and mox2-Cre mice
mediates germ line expression of endogenous oncogenic
NRASD12 [6], however, the cellular and pathological
mechanisms for the embryonic lethality in those studies
are unknown. Here we show that the expression of
oncogenic hNRASD12 during zebrafish embryogenesis
induces embryonic lethality through disrupting the
arterial-venous cell fate decision, offering a possible
mechanistic explanation for the oncogenic Ras signaling
induced embryonic lethality. Nevertheless, the pheno-
types of endothelial development need to be further ex-
amined in those mice models [6,39].
Figure 8 The medial migration of angioblasts in the posterior
bilateral mesoderm is not affected by the activated N-Ras
signaling. (A-J) The distribution of flk1
+ angioblasts at the posterior
lateral plate mesoderm in the control (A-E) and hNRASD12 embryos
(F-J) from 14 to 18 hpf.
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model organism that is suitable for large-scaled whole-
animal small chemical molecule screening, contributing
to several aspects of the drug development process, in-
cluding target identification, disease modeling, lead dis-
covery and toxicology [40]. The oncogenic NRASD12-
expressing mice develop leukemias in adult stage [4-7],
and are not suitable for drug screening due to the cost
and the large size of an individual, while the NRASD12
transgenic zebrafish embryos may be helpful for us to
perform large-scaled whole-animal small chemical mol-
ecule screening to find oncogenic NRASD12-associated
modulators using a developmental stage-controlled ex-
pression of oncogenic NRASD12.
Conclusions
In conclusion, we report firstly the constitutively ac-
tivated N-Ras signaling regulates the arterial-venous
specification in vertebrate, and also established an onco-
genic hNRASD12 induced animal disease model that is
feasible for high-throughput whole-animal drug screen-
ing and validating the functionality of NRASD12 modu-
lators as potential therapeutics for a variety of human
diseases caused by oncogenic mutant RAS.
Methods
Fish care
Zebrafish maintenance, breeding, and staging were
performed as previously described [41]. The zebrafish
experiments were approved by the Animal Experimen-
tation Committee of Shanghai Institutes for Biological
Sciences and institutional review board of Institute of
Health Sciences.
Generation of Tg(β-actin:LDL-hNRASD12) transgenic line
Human NRASD12 (hNRASD12) was obtained by PCR
from a myc-tagged NRASD12 in a retroviral vector [4]
and cloned into pCS2+ vector at the ClaI and XhoI
sites to get the hNRASD12-pCS2+ construct. Then
the hNRASD12-SV40 fragment was excised from
hNRASD12-pCS2+ plasmid by ClaI and KpnI and
cloned into the same sites of β-actin-loxP-DsRed-SV40-
loxP-PBSK-I-SceI plasmid [16] to get the β-actin-loxP-
DsRed-SV40-loxP-hNRASD12-PBSK-I-SceI transgenic
construct. Then this construct was co-injected with I-SceI
meganuclease (New England Biolabs) into the fertilized
zebrafish eggs at one cell stage. The injected embryos were
raised to adulthood and crossed to wild-type fish to gener-
ate the F1 progeny, and the transgenic founders were
identified by screening for the F1 embryos, expressing
DsRed fluorescence at 24 hours post fertilization (hpf).
We raised the DsRed
+ F1 embryos to adulthood to estab-
lish the stable transgenic lines.
Transient transgenic constructs
The zebrafish lmo2 promoter of 2.5 kbp was obtained by
PCR amplification from the lmo2-Cre-PBSK-I-SceI plas-
mid [16] and cloned into the EGFP-2A-pDestTol2 plas-
mid (Z.W.Dong et al., unpublished data) at the XhoI and
BamHI sites to get the lmo2-EGFP-2A-pDestTol2 con-
struct. Then the human NRASD12 (hNRASD12) and
zebrafish NRASD12 (zNRASD12) fragments were ob-
tained by PCR from the β-actin-loxP-DsRed-SV40-loxP-
hNRASD12-PBSK-I-SceI plasmid and cDNA from the
wild-type embryos respectively, and cloned into the lmo2-
EGFP-2A-pDestTol2 construct at the XmaI and SalI
sites to get the lmo2-EGFP-2A-hNRASD12/ zNRASD12-
pDestTol2 constructs. Of note, the forward primer for the
amplification of zebrafish NRASD12 contains mutations
at the codon 12 from GGA to GAT, resulting in the
substitution of glycine (G) to aspartic acid (D). Then the
lmo2-EGFP-2A-pDestTol2, lmo2-EGFP-2A-hNRASD12-
pDestTol2 and lmo2-EGFP-2A-zNRASD12- pDestTol2
transgenic plasmids (25 ng/ul) were individually co-
injected with KCl (0.2 M) and Tol2 transposase mRNA
(25 ng/ul) as previously described [42] into the Tg(flk1:
mCherry) or wild-type zebrafish embryos at one cell stage.
To generate the construct of the zebrafish flk1 pro-
moter driven NICD1, the HA-tagged NICD1 fragment
was obtained by PCR from the PME-NICD1 (zebrafish)
plasmid and cloned into the flk1-PolyA-pBSKI2 plas-
mid at the BamHI and EcoRI sites to get the flk1-HA-
NICD1-PolyA-pBSKI2 construct. Then the construct was
co-injected with I-SceI meganuclease into the hNRASD12
transgenic embryos at one cell stage.
Morpholino (MO)
Embryos were injected with 2 nl human NRAS ATG
MO (Gene Tools): 5’-ACCAGTTTGTACTCAGTCATAT
CGA-3’. The efficiency of hNRAS MO was confirmed
both by western blotting and co-injection with hNRAS
1-60-
GFP mRNA reporter containing the targeting sites of
hNRAS MO.
Preparation of mRNAs and antisense probes, whole-
mount in situ hybridization (WISH)
A 60 bp fragment of human NRAS that contains the
hNRAS ATG MO binding sites was fused to the N ter-
minal of GFP in the pCS2+ vector to get the hNRAS
1-60-
GFP-pCS2+ construct. The hNRAS
1-60-GFP, zebrafish
vegfaa121 [35] and Tol2 transposase [43] mRNAs were
synthesized with mMESSAGE mMACHINE Kit (Ambion).
The digoxigenin- or fluorescein-labelled antisense
probes used for WISH analysis in this study includes
lmo2 [16], (shh, notch1) [17], vegfaa121 [35], (plcg1, pu.1,
l-plastin, mpo, gata1, αe1 globin, flk1) [44], (cmyb,
runx1) [45], (ephrinB2, hRT, grl, notch3) [23], (dab2,
ephB4 and flt4) [28]. And the hNRASD12, zNRASD12,
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their digoxigenin-labelled antisense probes were synthe-
sized with T3 polymerase (Ambion).
Single- and 2-color WISH were performed as de-
scribed previously [17]. Embryos were mounted in 3%
methylcellulose and captured under the Nikon SMZ1500
microscope equipped with a Nikon DXM1200F digital
camera and ACT-1 software.
Genomic DNA isolation and genotyping
Embryos were incubated in lysis buffer (Tris–HCl 1 M,
pH 8.3; KCl 1 M; Tween 20 10%; NP40 10%) and pro-
tease K (10 mg/ml) at 55°C overnight. Then 3700 rpm
for 10 min at 4°C, and the supernatant was subject to gen-
omic PCR with specific primers for Cre and hNRASD12.
Real-time Quantitative PCR
Total RNAs were extracted from 20 zebrafish embryos
using Trizol reagent (Invitrogen). RNA was reverse-
transcribed using random hexamers and SuperScript III
Reverse Transcriptase (Invitrogen). 2×PCR Mix (TaKaRa,
Premix Ex Taq™) containing SYBR Green I was used for
the real-time quantitative PCR analysis with the Applied
Biosystems 7900HT Fast Real-Time PCR System. The
relative expression values were normalized against the in-
ternal control gapdh (qPCR primer sequences were listed
in Additional file 5: Table S1).
Western blotting and immunofluorescence
The western blotting assay was performed as described
previously [17] with antibodies: human NRAS (Santa
Cruz), GAPDH (Cell Signaling Technology). Immuno-
histochemistry was performed as described previously
[25], and the trunk of embryo was transversely sectioned
with a Leica VT1000S vibratome into 50–100 μms e c -
tions, and F-actin was stained with Phalloidin-TRITC
(0.007 μM, Sigma), and GFP antibody (Invitrogen, A6455)
was used. Sections were mounted with Dako-fluorescent
mounting media (Dako North America) prior to imaging
with an Olympus FV 1000 confocal microscopy.
Fluorescence microangiography
The fluorescein-coupled latex beads (Molecular Probes)
were injected into the inflow tract of the atrium of the
zebrafish embryo at 30 hpf with a dose of 2 nl. The
beads flowed with blood circulation and labeled all the
vascular vessels of wild-type embryos in 5 minutes.
Flow cytometry analysis
Embryos at 28 hpf were dissected in DPBS (Invitrogen)
after dechorionation and deyolking [46], and digested
with 1× trypsin/EDTA (Life Technologies) for 30 min at
28.5°C. Single cell suspension was obtained by centrifu-
gation at 400 g for 5 min, washed twice with 0.9XPBS/
5%FBS, and passed through a 40 μm nylon mesh filter.
Fluorescence-activated cell sorting was performed with
FACSAria (BD Biosciences) to quantify the frequency of
the GFP
+ endothelial cells.
Image analysis
Embryos were imaged under an Olympus FV 1000 con-
focal microscopy equipped with the FV10-ASW version3
software.
Statistical analysis
The values were represented as mean ± SEM. Two-tailed
students’t-tests were used for two groups comparison ana-
lysis, and P < 0.05 was considered to be significant. The
bar charts were used to reflect the alterations of experi-
mental data.
Additional files
Additional file 1: Movie S3. The blood circulation in the trunk of
β-actin:LDL-hNRASD12;lmo2:Cre embryo at 28 hpf.
Additional file 2: Movie S4. The blood circulation in the head of
β-actin:LDL-hNRASD12;lmo2:Cre embryo at 28 hpf.
Additional file 3: Movie S1. The blood circulation in the trunk of
β-actin:LDL-hNRASD12;wild-type embryo at 28 hpf.
Additional file 4: Movie S2. The blood circulation in the head of β-
actin:LDL-hNRASD12;wild-type embryo at 28 hpf.
Additional file 5: Supplementary figures and table.
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